Skip to main content

Table 3 Clinical data for the study population (n = 49) at baseline, 15, and 30 weeks.

From: Changes in pain and insulin-like growth factor 1 in fibromyalgia during exercise: the involvement of cerebrospinal inflammatory factors and neuropeptides

  Baseline
median (range)
15 weeks
median (range)
15-0 weeks
difference median (range)
Pvalue 30 weeks
median (range)
30 to 0 weeks
difference
median
(range)
Pvalue
Pain threshold kPa 202.8 (105.9-380.5) 189.9 (112.2-305.3) -9.6 (-102.1-75.6) 0.040 194.3 (107.6-472.3) -8.8 (-165.2-108.5) 0.608
Pain
0 to 100
71 (7-98) 65.5 (3-99) -5 (-40-35) 0.052 67 (14-95) -2 (-39-53) 0.365
6MWT
m
518 (381-660) 566 (418-689 25.1 (-77-164.5) < 0.001 555 (367.5-661) 15.5 (-150.5-145) 0.009
IGF-1
ng/ml
4.2 (0-35.7) 3.0 (0-33.8) -0.2 (-31.6-28.7) 0.085 2.7 (0-10.9) -0.7 (-31.2-1.7) 0.004
IGFB3
ng/ml
1,549.4 (2,69.5-3,288.3) 1,634 (182.4-2,967.3) -57.5 (-1,551.7-1,846.6) 0.889 1,795.4 (98.3-4,156.7) 272.9 (-1,563-2,821.8) 0.413